252 related articles for article (PubMed ID: 31300870)
1. Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.
Lettau M; Dietz M; Vollmers S; Armbrust F; Peters C; Dang TM; Chitadze G; Kabelitz D; Janssen O
Cell Mol Life Sci; 2020 Feb; 77(4):751-764. PubMed ID: 31300870
[TBL] [Abstract][Full Text] [Related]
2. CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context.
De Chiara L; Páez de la Cadena M; Rodríguez-Berrocal J; Alvarez-Pardiñas MC; Pardiñas-Añón MC; Varela-Calviño R; Cordero OJ
Dis Markers; 2020; 2020():4347936. PubMed ID: 32051696
[TBL] [Abstract][Full Text] [Related]
3. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes.
Aso Y; Terasawa T; Kato K; Jojima T; Suzuki K; Iijima T; Kawagoe Y; Mikami S; Kubota Y; Inukai T; Kasai K
Transl Res; 2013 Nov; 162(5):309-16. PubMed ID: 23994650
[TBL] [Abstract][Full Text] [Related]
4. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
5. The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells.
Chitadze G; Wehkamp U; Janssen O; Brüggemann M; Lettau M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885056
[TBL] [Abstract][Full Text] [Related]
6. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus.
Lee SA; Kim YR; Yang EJ; Kwon EJ; Kim SH; Kang SH; Park DB; Oh BC; Kim J; Heo ST; Koh G; Lee DH
J Clin Endocrinol Metab; 2013 Jun; 98(6):2553-61. PubMed ID: 23539735
[TBL] [Abstract][Full Text] [Related]
7. Distinctive CD26 Expression on CD4 T-Cell Subsets.
Cordero OJ; Rafael-Vidal C; Varela-Calviño R; Calviño-Sampedro C; Malvar-Fernández B; García S; Viñuela JE; Pego-Reigosa JM
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680079
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
9. CD26/DPP4 - a potential biomarker and target for cancer therapy.
Enz N; Vliegen G; De Meester I; Jungraithmayr W
Pharmacol Ther; 2019 Jun; 198():135-159. PubMed ID: 30822465
[TBL] [Abstract][Full Text] [Related]
10. Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology.
Raha AA; Chakraborty S; Henderson J; Mukaetova-Ladinska E; Zaman S; Trowsdale J; Raha-Chowdhury R
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33205807
[TBL] [Abstract][Full Text] [Related]
11. The roles of dipeptidyl peptidase-4 and its inhibitors in the regulation of airway epithelial-mesenchymal transition.
Sun J; Chu S; Lu M; Pan Q; Li D; Zheng S; Ma L
Exp Lung Res; 2020; 46(6):163-173. PubMed ID: 32292085
[No Abstract] [Full Text] [Related]
12. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs.
Ohnuma K; Munakata Y; Ishii T; Iwata S; Kobayashi S; Hosono O; Kawasaki H; Dang NH; Morimoto C
J Immunol; 2001 Dec; 167(12):6745-55. PubMed ID: 11739489
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko Y; Hatano R; Hirota N; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Valleix F; Podoll T; Umezawa Y; Takao S; Iwata S; Hosono O; Taguchi T; Yamada T; Dang NH; Ohnuma K; Angevin E; Morimoto C
Biomark Res; 2021 Mar; 9(1):21. PubMed ID: 33757558
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Matteucci E; Giampietro O
Curr Med Chem; 2009; 16(23):2943-51. PubMed ID: 19689275
[TBL] [Abstract][Full Text] [Related]
15. CD26 expression is down-regulated on CD8
Liu Y; Li Y; Gong Y; Yu N; Zhang Y; You R; Qu C; Lu G; Huang Y; Gao Y; Gao Y; Guo X
Int Immunopharmacol; 2018 Jan; 54():280-285. PubMed ID: 29175506
[TBL] [Abstract][Full Text] [Related]
16. Expansion of a CD26low Effector TH Subset and Reduction in Circulating Levels of sCD26 in Stable Allergic Asthma in Adults.
Nieto-Fontarigo JJ; González-Barcala FJ; San-José ME; Cruz MJ; Linares T; Soto-Mera MT; Valdés-Cuadrado L; García-González MA; Andrade-Bulos LJ; Arias P; Nogueira M; Salgado FJ
J Investig Allergol Clin Immunol; 2018; 28(2):113-125. PubMed ID: 29297467
[TBL] [Abstract][Full Text] [Related]
17. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation.
Leicht S; Shipkova M; Klett C; Gert H; Altrock E; Wilhelm J; Bolley R; Wollmeyer J; Ender A; Luz B; Olbricht C; Wieland E
Clin Biochem; 2013 Oct; 46(15):1383-8. PubMed ID: 23608353
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.
Hu X; Wang X; Xue X
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889373
[TBL] [Abstract][Full Text] [Related]
19. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response.
Iwata S; Yamaguchi N; Munakata Y; Ikushima H; Lee JF; Hosono O; Schlossman SF; Morimoto C
Int Immunol; 1999 Mar; 11(3):417-26. PubMed ID: 10221653
[TBL] [Abstract][Full Text] [Related]
20. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
Jang JH; Janker F; De Meester I; Arni S; Borgeaud N; Yamada Y; Gil Bazo I; Weder W; Jungraithmayr W
Carcinogenesis; 2019 Apr; 40(2):324-334. PubMed ID: 30698677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
